CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Curing disease with CRISPR with Trevor Martin from Mammoth Biosciences

From TechCrunch

By Rebecca Szkutak

April 18, 2023

Curing disease with CRISPR with Trevor Martin from Mammoth Biosciences

Welcome back to Found, where we get the stories behind the startups.

This week Darrell and Becca are joined by Trevor Marti the co-founder and CEO of Mammoth Biosciences, a startup that uses CRISPR to diagnose and find treatments for genetic diseases. Trevor talked about what it is like to build a company surrounding novel tech with one of the scientists credited with creating it. He also talked about the sheer scope of problems this technology can solve and how the company decided where to start. Plus, he talks about how Mammoth thinks about public perception of the tech in an age where there is growing hostility toward science.

Subscribe to Found to hear more stories from founders each week.

Connect with us:

  1. On Twitter
  2. On Instagram
  3. Via email: found@techcrunch.com

Curing disease with CRISPR with Trevor Martin from Mammoth Biosciences by Rebecca Szkutak originally published on TechCrunch

Most Recent

Ant-backed Mynt, which runs mobile wallet app GCash, rose as much as 2.4% in Manila after raising $841M in the Philippines' largest-ever IPO, valuing it at ~$7B

The fintech company raised over $841 million from its IPO — A financial-technology company backed by Ant International climbed …

Oct 20, 2026

U.S. bans DeepSeek from government agency systems amid AI rift with China

U.S. Department of Homeland Security has banned DeepSeek-related technology from federal civilian agency IT systems.

Oct 19, 2026

Alibaba Backs Chinese Robovan Maker in $400 Million Fundraising

Neolix Technologies Co., a Chinese maker of driverless delivery vehicles, raised $400 million to fuel its global expansion.

Oct 19, 2026

Australia to Sue Facebook, TikTok for Alleged Breaches of Ban

Australia's government is set to sue Facebook, TikTok and other major digital platforms for alleged non-compliance …

Oct 19, 2026

Similar Posts

Making more mammoths with Ben Lamm from Colossal

Welcome back to Found, where we get the stories behind the startups. This week Darrell and Becca are joined by Ben Lamm, the founder and CEO of Colossal, a genetics startup that looks to bring extinct species back to life to help with environmental conservation efforts. Ben talked about how he got to this point […]

Mar 21, 2023

The academic to founder pipeline with Dr. Stacy Blain from Concarlo Therapeutics

Welcome back to Found, where we get the stories behind the startups. This week, Becca and Dom are joined by Stacy Blain, the co-founder and chief science officer at Concarlo Therapeutics. Blain talked about how she had been researching how to cure drug-resistant cancers before she accidentally found her way into entrepreneurship after her academic […]

May 30, 2023

Reed Jobs would rather talk about curing cancer than his last name

When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs' words, a huge part of what Yosemite does. "I didn't expect Yosemite to be moving this fast," he said.

Jul 11, 2026

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026